Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Lipoprotein(a) as a Predictive Biomarker and Therapeutic Target for Acute Coronary Syndromes

Author(s): Yannis Dimitroglou*, Constantina Aggeli, Panagiotis Theofilis, Panagiotis Tsioufis, Evangelos Oikonomou, Konstantinos Tsioufis and Dimitris Tousoulis

Volume 29, Issue 23, 2023

Published on: 06 June, 2023

Page: [1835 - 1843] Pages: 9

DOI: 10.2174/1381612829666230601155001

Price: $65

Abstract

Coronary artery disease (CAD) is the leading cause of morbidity and mortality in Western societies, despite the significant advances that have improved primary and secondary prevention. Hence, several novel biomarkers have been identified as potential diagnostic and therapeutic targets which could improve outcomes even when traditional risk factors are well-controlled. Lipoprotein (a) [Lp(a)] has pro-atherogenic, pro-thrombotic, and pro-inflammatory properties, and its levels are relatively constant and genetically predetermined. Several epidemiological studies have associated high Lp(a) with increased risk for acute coronary syndromes (ACS) even when other CAD risk factors are included in the multivariate analysis. However, until recently, specific therapeutic options targeting Lp(a) were not associated, and thus, Lp(a) is currently used as a risk and treatment modifying biomarker with guidelines suggesting the intensified treatment of low-density lipoprotein in intermediate- to-high-risk patients with increased Lp(a) levels. Lately, specific treatment options targeting Lp(a) have become available and include antisense oligonucleotides and small-interfering RNA, which induce a robust reduction of Lp(a). Results of ongoing phase-3 trials will answer whether Lp(a) will become a biomarker specifically treated to reduce the burden of cardiovascular mortality. The scope of this review article is to present the current evidence regarding the use of Lp(a) as a biomarker, predictive of increased CAD risk, and to discuss the future perspectives on pharmaceutical reduction of Lp(a) as a therapeutic target in high-risk patients.

Keywords: Lipoproteins, cardiovascular disease, myocardial infarction, antisense oligonucleotides, siRNA, CAD.

« Previous Next »
[1]
Roth GA, Abate D, Abate KH, et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018; 392(10159): 1736-88.
[http://dx.doi.org/10.1016/S0140-6736(18)32203-7] [PMID: 30496103]
[2]
Virani SS, Alonso A, Aparicio HJ, et al. Heart disease and stroke statistics—2021 update. Circulation 2021; 143(8): e254-743.
[http://dx.doi.org/10.1161/CIR.0000000000000950] [PMID: 33501848]
[3]
Dimitroglou Y, Sakalidis A, Mavroudis A, et al. Lipoprotein-associated phospholipase A2 in coronary artery disease. Curr Top Med Chem 2022; 12: 23.
[PMID: 36305124]
[4]
Sagris M, Antonopoulos AS, Theofilis P, et al. Risk factors profile of young and older patients with myocardial infarction. Cardiovasc Res 2022; 118(10): 2281-92.
[http://dx.doi.org/10.1093/cvr/cvab264] [PMID: 34358302]
[5]
Theofilis P, Sagris M, Oikonomou E, et al. Inflammatory mechanisms contributing to endothelial dysfunction. Biomedicines 2021; 9(7): 781.
[http://dx.doi.org/10.3390/biomedicines9070781] [PMID: 34356845]
[6]
Oikonomou E, Lampsas S, Pantelidis P, et al. Lipoprotein (a) levels and abdominal aortic aneurysm. A systematic review and meta-analysis. Curr Pharm Des 2022; 28(43): 3492-9.
[http://dx.doi.org/10.2174/1381612829666221124110920] [PMID: 36424795]
[7]
Kostner KM, Kostner GM. Lipoprotein (a): A historical appraisal. J Lipid Res 2017; 58(1): 1-14.
[http://dx.doi.org/10.1194/jlr.R071571] [PMID: 27821413]
[8]
Tsimikas S. A test in context: Lipoprotein(a). J Am Coll Cardiol 2017; 69(6): 692-711.
[http://dx.doi.org/10.1016/j.jacc.2016.11.042] [PMID: 28183512]
[9]
Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, et al. Lipoprotein(a). N Engl J Med 2020; 382(3): 244-55.
[http://dx.doi.org/10.1056/NEJMoa1905239] [PMID: 31893580]
[10]
O’Donoghue ML, Rosenson RS, Gencer B, et al. Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease. N Engl J Med 2022; 387(20): 1855-64.
[http://dx.doi.org/10.1056/NEJMoa2211023] [PMID: 36342163]
[11]
McLean JW, Tomlinson JE, Kuang WJ, et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987; 330(6144): 132-7.
[http://dx.doi.org/10.1038/330132a0] [PMID: 3670400]
[12]
Schmidt K, Noureen A, Kronenberg F, Utermann G. Structure, function, and genetics of lipoprotein(a). J Lipid Res 2016; 57(8): 1339-59.
[http://dx.doi.org/10.1194/jlr.R067314] [PMID: 27074913]
[13]
Chemello K, Chan DC, Lambert G, Watts GF. Recent advances in demystifying the metabolism of lipoprotein(a). Atherosclerosis 2022; 349: 82-91.
[http://dx.doi.org/10.1016/j.atherosclerosis.2022.04.002] [PMID: 35606080]
[14]
Brunner C, Lobentanz EM, Pethö-Schramm A, et al. The number of identical kringle IV repeats in apolipoprotein(a) affects its processing and secretion by HepG2 cells. J Biol Chem 1996; 271(50): 32403-10.
[http://dx.doi.org/10.1074/jbc.271.50.32403] [PMID: 8943305]
[15]
Lobentanz EM, Krasznai K, Gruber A, et al. Intracellular metabolism of human apolipoprotein(a) in stably transfected Hep G2 cells. Biochemistry 1998; 37(16): 5417-25.
[http://dx.doi.org/10.1021/bi972761t] [PMID: 9548923]
[16]
Kraft HG, Köchl S, Menzel HJ, Sandholzer C, Utermann G. The apolipoprotein (a) gene: A transcribed hypervariable locus controlling plasma lipoprotein (a) concentration. Hum Genet 1992; 90(3): 220-30.
[http://dx.doi.org/10.1007/BF00220066] [PMID: 1336760]
[17]
Coassin S, Kronenberg F. Lipoprotein(a) beyond the kringle IV repeat polymorphism: The complexity of genetic variation in the LPA gene. Atherosclerosis 2022; 349: 17-35.
[http://dx.doi.org/10.1016/j.atherosclerosis.2022.04.003] [PMID: 35606073]
[18]
Bonen DK, Hausman AL, Hadjiagapiou C, Skarosi SF, Davidson NO. Expression of a recombinant apolipoprotein(a) in HepG2 cells. Evidence for intracellular assembly of lipoprotein(a). J Biol Chem 1997; 272(9): 5659-67.
[http://dx.doi.org/10.1074/jbc.272.9.5659] [PMID: 9038176]
[19]
Reyes-Soffer G, Ginsberg HN, Ramakrishnan R. The metabolism of lipoprotein(a): an ever-evolving story. J Lipid Res 2017; 58(9): 1756-64.
[http://dx.doi.org/10.1194/jlr.R077693] [PMID: 28720561]
[20]
Tsimikas S, Gordts PLSM, Nora C, Yeang C, Witztum JL. Statin therapy increases lipoprotein(a) levels. Eur Heart J 2020; 41(24): 2275-84.
[http://dx.doi.org/10.1093/eurheartj/ehz310] [PMID: 31111151]
[21]
Romagnuolo R, Scipione CA, Boffa MB, Marcovina SM, Seidah NG, Koschinsky ML. Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor. J Biol Chem 2015; 290(18): 11649-62.
[http://dx.doi.org/10.1074/jbc.M114.611988] [PMID: 25778403]
[22]
Mack S, Coassin S, Rueedi R, et al. A genome-wide association meta-analysis on lipoprotein (a) concentrations adjusted for apolipoprotein (a) isoforms. J Lipid Res 2017; 58(9): 1834-44.
[http://dx.doi.org/10.1194/jlr.M076232] [PMID: 28512139]
[23]
Yang XP, Amar MJ, Vaisman B, et al. Scavenger receptor-BI is a receptor for lipoprotein(a). J Lipid Res 2013; 54(9): 2450-7.
[http://dx.doi.org/10.1194/jlr.M038877] [PMID: 23812625]
[24]
Sharma M, Redpath GM, Williams MJA, McCormick SPA. Recycling of apolipoprotein(a) after PlgRKT-mediated endocytosis of lipoprotein(a). Circ Res 2017; 120(7): 1091-102.
[http://dx.doi.org/10.1161/CIRCRESAHA.116.310272] [PMID: 28003220]
[25]
Cegla J, France M, Marcovina SM, Neely RDG. Lp(a): When and how to measure it. Ann Clin Biochem 2021; 58(1): 16-21.
[http://dx.doi.org/10.1177/0004563220968473] [PMID: 33040574]
[26]
Duarte Lau F, Giugliano RP. Lipoprotein(a) and its significance in cardiovascular disease. JAMA Cardiol 2022; 7(7): 760-9.
[http://dx.doi.org/10.1001/jamacardio.2022.0987] [PMID: 35583875]
[27]
Marcovina SM, Albers JJ, Gabel B, Koschinsky ML, Gaur VP. Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a). Clin Chem 1995; 41(2): 246-55.
[http://dx.doi.org/10.1093/clinchem/41.2.246] [PMID: 7533064]
[28]
Dati F, Tate JR, Marcovina SM, Steinmetz A. First WHO/IFCC international reference reagent for lipoprotein(a) for immunoassay-Lp(a) SRM 2B. Clin Chem Lab Med 2004; 42(6): 670-6.
[http://dx.doi.org/10.1515/CCLM.2004.114] [PMID: 15259385]
[29]
Reyes-Soffer G, Ginsberg HN, Berglund L, et al. Lipoprotein(a): A genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the american heart association. Arterioscler Thromb Vasc Biol 2022; 42(1): e48-60.
[http://dx.doi.org/10.1161/ATV.0000000000000147] [PMID: 34647487]
[30]
Wilson DP, Jacobson TA, Jones PH, et al. Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. J Clin Lipidol 2022; 16(5): e77-95.
[http://dx.doi.org/10.1016/j.jacl.2022.08.007] [PMID: 36068139]
[31]
Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41(1): 111-88.
[http://dx.doi.org/10.1093/eurheartj/ehz455] [PMID: 31504418]
[32]
Kronenberg F. Lipoprotein(a) measurement issues: Are we making a mountain out of a molehill? Atherosclerosis 2022; 349: 123-35.
[http://dx.doi.org/10.1016/j.atherosclerosis.2022.04.008] [PMID: 35606072]
[33]
Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J 2022; 43(39): 3925-46.
[http://dx.doi.org/10.1093/eurheartj/ehac361] [PMID: 36036785]
[34]
Varvel S, McConnell JP, Tsimikas S. Prevalence of elevated Lp(a) mass levels and patient thresholds in 532 359 patients in the United States. Arterioscler Thromb Vasc Biol 2016; 36(11): 2239-45.
[http://dx.doi.org/10.1161/ATVBAHA.116.308011] [PMID: 27659098]
[35]
Guan W, Cao J, Steffen BT, et al. Race is a key variable in assigning lipoprotein(a) cutoff values for coronary heart disease risk assessment: The Multi-Ethnic Study of Atherosclerosis. Arterioscler Thromb Vasc Biol 2015; 35(4): 996-1001.
[http://dx.doi.org/10.1161/ATVBAHA.114.304785] [PMID: 25810300]
[36]
Deshotels MR, Sun C, Nambi V, et al. Temporal trends in lipoprotein(a) concentrations: The atherosclerosis risk in communities study. J Am Heart Assoc 2022; 11(21): e026762.
[http://dx.doi.org/10.1161/JAHA.122.026762] [PMID: 36285784]
[37]
Sniderman AD, Thanassoulis G, Glavinovic T, et al. Apolipoprotein B particles and cardiovascular disease. JAMA Cardiol 2019; 4(12): 1287-95.
[http://dx.doi.org/10.1001/jamacardio.2019.3780] [PMID: 31642874]
[38]
Marcovina SM, Koschinsky ML. Evaluation of lipoprotein(a) as a prothrombotic factor: Progress from bench to bedside. Curr Opin Lipidol 2003; 14(4): 361-6.
[http://dx.doi.org/10.1097/00041433-200308000-00004] [PMID: 12865733]
[39]
Boffa MB. Beyond fibrinolysis: The confounding role of Lp(a) in thrombosis. Atherosclerosis 2022; 349: 72-81.
[http://dx.doi.org/10.1016/j.atherosclerosis.2022.04.009] [PMID: 35606079]
[40]
Simantiris S, Antonopoulos AS, Papastamos C, et al. Lipoprotein(a) and inflammation- pathophysiological links and clinical implications for cardiovascular disease. J Clin Lipidol 2023; 17(1): 55-63.
[http://dx.doi.org/10.1016/j.jacl.2022.10.004] [PMID: 36333256]
[41]
Boffa MB, Marcovina SM, Koschinsky ML. Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal models. Clin Biochem 2004; 37(5): 333-43.
[http://dx.doi.org/10.1016/j.clinbiochem.2003.12.007] [PMID: 15087247]
[42]
Lawn RM, Wade DP, Hammer RE, Chiesa G, Verstuyft JG, Rubin EM. Atherogenesis in transgenic mice expressing human apolipoprotein(a). Nature 1992; 360(6405): 670-2.
[http://dx.doi.org/10.1038/360670a0] [PMID: 1465128]
[43]
Fan J, Shimoyamada H, Sun H, Marcovina S, Honda K, Watanabe T. Transgenic rabbits expressing human apolipoprotein(a) develop more extensive atherosclerotic lesions in response to a cholesterol-rich diet. Arterioscler Thromb Vasc Biol 2001; 21(1): 88-94.
[http://dx.doi.org/10.1161/01.ATV.21.1.88] [PMID: 11145938]
[44]
Keesler GA, Li Y, Skiba PJ, Fless GM, Tabas I. Macrophage foam cell lipoprotein(a)/apoprotein(a) receptor. Cell-surface localization, dependence of induction on new protein synthesis, and ligand specificity. Arterioscler Thromb 1994; 14(8): 1337-45.
[http://dx.doi.org/10.1161/01.ATV.14.8.1337] [PMID: 8049196]
[45]
Kang C, Dominguez M, Loyau S, Miyata T, Durlach V, Anglés-Cano E. Lp(a) particles mold fibrin-binding properties of apo(a) in size-dependent manner: a study with different-length recombinant apo(a), native Lp(a), and monoclonal antibody. Arterioscler Thromb Vasc Biol 2002; 22(7): 1232-8.
[http://dx.doi.org/10.1161/01.ATV.0000021144.87870.C8] [PMID: 12117743]
[46]
Sangrar W, Bajzar L, Nesheim ME, Koschinsky ML. Antifibrinolytic effect of recombinant apolipoprotein(a) in vitro is primarily due to attenuation of tPA-mediated Glu-plasminogen activation. Biochemistry 1995; 34(15): 5151-7.
[http://dx.doi.org/10.1021/bi00015a028] [PMID: 7711034]
[47]
Hancock MA, Boffa MB, Marcovina SM, Nesheim ME, Koschinsky ML. Inhibition of plasminogen activation by lipoprotein(a): critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces. J Biol Chem 2003; 278(26): 23260-9.
[http://dx.doi.org/10.1074/jbc.M302780200] [PMID: 12697748]
[48]
Rand ML, Sangrar W, Hancock MA, et al. Apolipoprotein(a) enhances platelet responses to the thrombin receptor-activating peptide SFLLRN. Arterioscler Thromb Vasc Biol 1998; 18(9): 1393-9.
[http://dx.doi.org/10.1161/01.ATV.18.9.1393] [PMID: 9743227]
[49]
Caplice NM, Panetta C, Peterson TE, et al. Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: A novel link between lipoproteins and thrombosis. Blood 2001; 98(10): 2980-7.
[http://dx.doi.org/10.1182/blood.V98.10.2980] [PMID: 11698280]
[50]
Bergmark C, Dewan A, Orsoni A, et al. A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma. J Lipid Res 2008; 49(10): 2230-9.
[http://dx.doi.org/10.1194/jlr.M800174-JLR200] [PMID: 18594118]
[51]
Zhivaki D, Kagan JC. Innate immune detection of lipid oxidation as a threat assessment strategy. Nat Rev Immunol 2022; 22(5): 322-30.
[http://dx.doi.org/10.1038/s41577-021-00618-8] [PMID: 34548649]
[52]
Hoogeveen RC, Ballantyne CM. Residual cardiovascular risk at low LDL: Remnants, Lipoprotein(a), and inflammation. Clin Chem 2021; 67(1): 143-53.
[http://dx.doi.org/10.1093/clinchem/hvaa252] [PMID: 33257928]
[53]
Tsimikas S, Brilakis ES, Miller ER, et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med 2005; 353(1): 46-57.
[http://dx.doi.org/10.1056/NEJMoa043175] [PMID: 16000355]
[54]
van der Valk FM, Bekkering S, Kroon J, et al. Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans. Circulation 2016; 134(8): 611-24.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.116.020838] [PMID: 27496857]
[55]
Schnitzler JG, Hoogeveen RM, Ali L, et al. Atherogenic Lipoprotein(a) increases vascular glycolysis, thereby facilitating inflammation and leukocyte extravasation. Circ Res 2020; 126(10): 1346-59.
[http://dx.doi.org/10.1161/CIRCRESAHA.119.316206] [PMID: 32160811]
[56]
Takami S, Yamashita S, Kihara S, et al. Lipoprotein(a) enhances the expression of intercellular adhesion molecule-1 in cultured human umbilical vein endothelial cells. Circulation 1998; 97(8): 721-8.
[http://dx.doi.org/10.1161/01.CIR.97.8.721] [PMID: 9498534]
[57]
Yuan X, Han Y, Hu X, et al. Lipoprotein (a) is related to in-stent neoatherosclerosis incidence rate and plaque vulnerability: Optical coherence tomography study. Int J Cardiovasc Imaging 2022; 39(2): 275-84.
[PMID: 36315364]
[58]
Rosengren A, Wilhelmsen L, Eriksson E, Risberg B, Wedel H. Lipoprotein(a) and coronary heart disease: A prospective case-control study in a general population sample of middle aged men. BMJ 1990; 301(6763): 1248-51.
[http://dx.doi.org/10.1136/bmj.301.6763.1248] [PMID: 2148699]
[59]
Nguyen TT, Ellefson RD, Hodge DO, Bailey KR, Kottke TE, Abu-Lebdeh HS. Predictive value of electrophoretically detected lipoprotein(a) for coronary heart disease and cerebrovascular disease in a community-based cohort of 9936 men and women. Circulation 1997; 96(5): 1390-7.
[http://dx.doi.org/10.1161/01.CIR.96.5.1390] [PMID: 9315522]
[60]
Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 2000; 102(10): 1082-5.
[http://dx.doi.org/10.1161/01.CIR.102.10.1082] [PMID: 10973834]
[61]
Kamstrup PR, Benn M, Tybjærg-Hansen A, Nordestgaard BG. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: The Copenhagen City Heart Study. Circulation 2008; 117(2): 176-84.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.107.715698] [PMID: 18086931]
[62]
Patel AP, Wang M, Pirruccello JP, et al. Lipoprotein(a) concentrations and incident atherosclerotic cardiovascular disease: new insights from a large national biobank. Arterioscler Thromb Vasc Biol 2021; 41: 465.
[PMID: 33115266]
[63]
Rallidis LS, Pavlakis G, Foscolou A, et al. High levels of lipoprotein(a) and premature acute coronary syndrome. Atherosclerosis 2018; 269: 29-34.
[http://dx.doi.org/10.1016/j.atherosclerosis.2017.12.011] [PMID: 29258004]
[64]
Waldeyer C, Makarova N, Zeller T, et al. Lipoprotein(a) and the risk of cardiovascular disease in the European population: results from the BiomarCaRE consortium. Eur Heart J 2017; 38(32): 2490-8.
[http://dx.doi.org/10.1093/eurheartj/ehx166] [PMID: 28449027]
[65]
Foscolou A, Georgousopoulou E, Magriplis E, et al. The mediating role of Mediterranean diet on the association between Lp(a) levels and cardiovascular disease risk: A 10-year follow-up of the ATTICA study. Clin Biochem 2018; 60: 33-7.
[http://dx.doi.org/10.1016/j.clinbiochem.2018.07.011] [PMID: 30055165]
[66]
O’Donoghue ML, Morrow DA, Tsimikas S, et al. Lipoprotein(a) for risk assessment in patients with established coronary artery disease. J Am Coll Cardiol 2014; 63(6): 520-7.
[http://dx.doi.org/10.1016/j.jacc.2013.09.042] [PMID: 24161323]
[67]
Khera AV, Everett BM, Caulfield MP, et al. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). Circulation 2014; 129(6): 635-42.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.113.004406] [PMID: 24243886]
[68]
Bittner VA, Szarek M, Aylward PE, et al. Effect of Alirocumab on Lipoprotein(a) and cardiovascular risk after acute coronary syndrome. J Am Coll Cardiol 2020; 75(2): 133-44.
[http://dx.doi.org/10.1016/j.jacc.2019.10.057] [PMID: 31948641]
[69]
Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 2009; 301(22): 2331-9.
[http://dx.doi.org/10.1001/jama.2009.801] [PMID: 19509380]
[70]
Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009; 361(26): 2518-28.
[http://dx.doi.org/10.1056/NEJMoa0902604] [PMID: 20032323]
[71]
Kyriakou T, Seedorf U, Goel A, et al. A common LPA null allele associates with lower lipoprotein(a) levels and coronary artery disease risk. Arterioscler Thromb Vasc Biol 2014; 34(9): 2095-9.
[http://dx.doi.org/10.1161/ATVBAHA.114.303462] [PMID: 24925971]
[72]
Scanu AM, Bamba R. Niacin and lipoprotein(a): Facts, uncertainties, and clinical considerations. Am J Cardiol 2008; 101(8): S44-7.
[http://dx.doi.org/10.1016/j.amjcard.2008.02.031] [PMID: 18375241]
[73]
Boden WE, Probstfield JL, Andrerson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365: 2255-67.
[74]
Landray MJ, Haynes R, Hopewell JC, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 2014; 371(3): 203-12.
[http://dx.doi.org/10.1056/NEJMoa1300955] [PMID: 25014686]
[75]
Leebmann J, Roeseler E, Julius U, et al. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study. Circulation 2013; 128(24): 2567-76.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.113.002432] [PMID: 24056686]
[76]
Roeseler E, Julius U, Heigl F, et al. Lipoprotein apheresis for lipoprotein(a)-associated cardiovascular disease. Arterioscler Thromb Vasc Biol 2016; 36(9): 2019-27.
[http://dx.doi.org/10.1161/ATVBAHA.116.307983] [PMID: 27417585]
[77]
Hohenstein B, Julius U, Lansberg P, et al. Rationale and design of MultiSELECt: A European Multi center S tudy on the E ffect of L ipoprotein(a) E limination by lipoprotein apheresis on C ardiovascular ou t comes. Atheroscler Suppl 2017; 30: 180-6.
[http://dx.doi.org/10.1016/j.atherosclerosissup.2017.05.009] [PMID: 29096835]
[78]
Tsimikas S, Moriarty PM, Stroes ES. Emerging RNA therapeutics to lower blood levels of Lp(a). J Am Coll Cardiol 2021; 77(12): 1576-89.
[http://dx.doi.org/10.1016/j.jacc.2021.01.051] [PMID: 33766265]
[79]
Crooke ST, Geary RS. Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B. Br J Clin Pharmacol 2013; 76(2): 269-76.
[http://dx.doi.org/10.1111/j.1365-2125.2012.04469.x] [PMID: 23013161]
[80]
Merki E, Graham MJ, Mullick AE, et al. Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice. Circulation 2008; 118(7): 743-53.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.108.786822] [PMID: 18663084]
[81]
Santos RD, Raal FJ, Catapano AL, Witztum JL, Steinhagen-Thiessen E, Tsimikas S. Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials. Arterioscler Thromb Vasc Biol 2015; 35(3): 689-99.
[http://dx.doi.org/10.1161/ATVBAHA.114.304549] [PMID: 25614280]
[82]
Reeskamp LF, Kastelein JJP, Moriarty PM, et al. Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia. Atherosclerosis 2019; 280: 109-17.
[http://dx.doi.org/10.1016/j.atherosclerosis.2018.11.017] [PMID: 30500603]
[83]
Merki E, Graham M, Taleb A, et al. Antisense oligonucleotide lowers plasma levels of apolipoprotein(a) and lipoprotein(a) in transgenic mice. J Am Coll Cardiol 2011; 57(15): 1611-21.
[http://dx.doi.org/10.1016/j.jacc.2010.10.052] [PMID: 21474042]
[84]
Viney NJ, van Capelleveen JC, Geary RS, et al. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet 2016; 388(10057): 2239-53.
[http://dx.doi.org/10.1016/S0140-6736(16)31009-1] [PMID: 27665230]
[85]
Assessing the Impact of Lipoprotein(a) Lowering with Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients with CVD. Available from: https://clinicaltrials.gov/ct2/show/NCT04023552
[86]
Koren MJ, Moriarty PM, Baum SJ, et al. Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a). Nat Med 2022; 28(1): 96-103.
[http://dx.doi.org/10.1038/s41591-021-01634-w] [PMID: 35027752]
[87]
Nissen SE, Wolski K, Balog C, et al. Single ascending dose study of a short interfering RNA targeting lipoprotein(a) production in individuals with elevated plasma lipoprotein(a) levels. JAMA 2022; 327(17): 1679-87.
[http://dx.doi.org/10.1001/jama.2022.5050] [PMID: 35368052]

Rights & Permissions Print Cite
Article Metrics
28
3
© 2024 Bentham Science Publishers | Privacy Policy